Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study
Australasian Journal of Dermatology2022Vol. 63(3), pp. 312–320
Citations Over Time
Abstract
Secukinumab treatment demonstrated a striking improvement in patients' QoL in the HOPE study, the first real-world study in patients with severe chronic plaque psoriasis in the Australian clinical setting.
Related Papers
- → Intramuscular Alefacept Improves Health-Related Quality of Life in Patients with Chronic Plaque Psoriasis(2003)93 cited
- → A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis(2017)7 cited
- → Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study(2022)7 cited
- → Successful treatment of secukinumab in severe plaque psoriasis(2022)2 cited
- → Real-life experience of secukinumab injection in difficult chronic plaque-type psoriasis: a multicenter experience(2019)1 cited